Not only has the window for biotech initial public offerings (IPOs) remained wide open so far this year, but also the after-market performance of the newly minted public companies has been nothing short of amazing – recording a collective 68 percent increase in share price after hitting the markets. Not surprising then that companies on the biotech IPO runway have been anxious to take flight.